Boudewijns S, Westdorp H, Koornstra RHT, Aarntzen EHJG, Schreib elt G, Creemers JHA, et al. Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients. J Immunother. (2016) 39:241–8. doi:10.1097/CJI.0000000000000127 104. Nesselhut J, Marx D, Lange H, Regalo G, Cillien N, Chang RY, et a l. Systemictreatmentwithanti-PD-1antibodynivolumabincombinat ionwith vaccine therapy in advanced pancreatic cancer. J Clin Oncol . 2016 34:3092. doi:10.1200/JCO.2016.34.15_suppl.3092 105. Simon S, Labarriere N. PD-1 expression on tumor-speciﬁc T cells: friend or foe for immunotherapy? Oncoimmunology. (2017) 7:e1364828. doi:10.1080/2162402X.2017.1364828 106. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Eﬀect of daily aspirin on long-term risk of death due to cancer: analy sis of individual patient data from randomised trials. Lancet.(2011) 377:31–41.